Patents Assigned to Liquid Biopsy Research LLC
  • Predicting peptide receptor radiotherapy using a gene expression assay
    Patent number: 11744907
    Abstract: The present invention is directed to methods for providing a peptide receptor radiotherapy treatment recommendation for a subject having a neuroendocrine tumor by determining the expression level of each of at least 9 biomarkers comprising ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9. In some embodiments, the methods can further include determining the expression level of each of NAP1L1, NOL3, and TECPR2.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: September 5, 2023
    Assignee: Liquid Biopsy Research LLC
    Inventors: Irvin Mark Modlin, Mark Kidd, Ignat Drozdov
  • Methods for colon cancer detection and treatment
    Patent number: 11414707
    Abstract: The present invention is directed to methods for detecting a colon cancer, methods for determining whether a colon cancer is stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a colon cancer to a therapy.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: August 16, 2022
    Assignee: Liquid Biopsy Research LLC
    Inventors: Irvin Mark Modlin, Mark Kidd, Ignat Drozdov
  • Methods for prostate cancer detection and treatment
    Patent number: 11410748
    Abstract: The present invention is directed to methods for detecting a prostate cancer, methods for determining whether a prostate cancer is stable or progressive, low or high Gleason score, methods for differentiating benign prostate hyperplasia (BPH) from prostate cancer, methods for determining the completeness of surgery, and methods for evaluating the response to a prostate cancer therapy.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: August 9, 2022
    Assignee: Liquid Biopsy Research LLC
    Inventors: Irvin Mark Modlin, Mark Kidd, Ignat Drozdov
  • COMPOSITIONS, METHODS AND KITS FOR BIOLOGICAL SAMPLE AND RNA STABILIZATION
    Publication number: 20210108259
    Abstract: The present disclosure provides a buffer comprising at least one chaotropic agent, at least one chelating agent and at least one non-ionic surfactant, wherein the buffer stabilizes a biological sample at about room temperature for at least about one day.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 15, 2021
    Applicants: Liquid Biopsy Research LLC
    Inventors: Mark KIDD, Irvin Mark MODLIN, Ignat DROZDOV